# US 2011/0217311 A1 · Cycloalkyl containing thienopyrimidines for pharmaceutical compositions

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2011/0217311 A1
- Document ID: US20110217311A1
- Status: Published application
- Kind: A1
- Application number: 13/034,855
- Filed: 2011-02-25
- Published: 2011-09-08
- Earliest claimed: 2010-02-26
- Assignees: Boehringer Ingelheim International GmbH
- Inventors: Thorsten LEHMANN-LINTZ; Armin HECKEL; Joerg KLEY; Elke LANGKOPF; Nobert REDEMANN; Achim SAUER; Leo THOMAS; Dieter WIEDENMAYER; Matthias AUSTEN; John DANILEWICZ; Martin SCHNEIDER; Kay SCHREITER; Phillip BLACK; Wesley BLACKABY; Ian LINNEY
- Web page: https://patentgrep.com/patent/US20110217311A1

## CPC

- C07D 495/04: Ortho-condensed systems
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/02: Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- A61P 7/06: Antianaemics
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/12: Antihypertensives
- A61P 13/00: Drugs for disorders of the urinary system
- A61P 13/12: of the kidneys
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to novel thienopyrimidine compounds of general formula pharmaceutical compositions comprising these compounds and their therapeutic use for the prophylaxis and/or treatment of diseases which can be influenced by the inhibition of the kinase activity of Mnk1 and/or Mnk2 (Mnk2a or Mnk2b) and/or variants thereof.

## Claims

### Claim 1

A compound of Formula (I)
wherein
X is CH or N,
R1 is a hydrogen or halogen atom,
R2 is C3-7 cycloalkyl group that is substituted with one or two substituents selected from oxo, halogen, C1-3 alkyl, hydroxy, C1-3 alkoxy, C1-4 alkoxy-carbonyl, amino and morpholinyl,
wherein the hydrogen atoms of the amino group may optionally be independently replaced by a C1-3 alkyl, C1-3 alkoxy-(CH2)m—, C1-4 alkoxy-carbonyl, C1-3 alkylsulfonyl, C1-3 alkyl-carbonyl, C3-6-cycloalkyl-carbonyl or piperidinyl group, wherein m is 2 or 3 and wherein the piperidinyl group may optionally be substituted by a methyl group,
wherein two substituents, which are attached to the same carbon atom, together may form a —O—(CH2)2—O— group, and
wherein two substituents, which are attached to two adjacent carbon atoms, together may form a —O—CH2—O— or —O—C(CH3)2—O— group,
R3 is a C1-2 alkyl group and
R4 is a carboxy, C1-3 alkoxy-carbonyl, aminocarbonyl, N—(C1-4 alkyl)-aminocarbonyl or N,N-[di-(C1-4 alkyl)]-aminocarbonyl group,
wherein the aminocarbonyl group may be substituted with a C1-3 alkylsulfonyl, CN, OH, C1-3 alkoxy, C3-6 cycloalkyl, —CH2—C≡C—CH2—NH2, —CH2—C≡C—CH2—NH(C1-3 alkyl) or —CH2—C≡C—CH2—N(C1-3 alkyl)2 group or with a piperidinyl or pyrrolidinyl group bound via a carbon atom,
and
wherein the alkyl moieties of the above-mentioned N-(C1-4 alkyl)-amino-carbonyl and N,N-[di-(C1-4 alkyl)]-aminocarbonyl groups may optionally be substituted with an aminocarbonyl, N-(C1-3 alkyl)-aminocarbonyl or N,N-[di-(C1-3 alkyl)]-aminocarbonyl group or with a pyrrolidinyl, oxazolyl, imidazolyl, piperidinyl or morpholinyl group, each bound via a carbon atom, or, from position 2 of an ethyl, propyl or butyl moiety onwards, with a OH, CN, C1-3 alkoxy, amino, N-(C1-3 alkyl)-amino, N,N-[di-(C1-3 alkyl)]-amino, C1-5 alkyloxy-carbonyl-amino, morpholino, piperidino, piperazino, pyrrolidino, azetedinyl, aziridinyl or imidazolyl group,
wherein each of the above-mentioned cycloalkyl, pyrrolidinyl, oxazolyl, piperidinyl, morpholinyl, piperazinyl and imidazolyl groups may be substituted with a methyl, amino, hydroxy group or C1-3 alkoxy,
or a pharmaceutically acceptable salt thereof.

### Claim 2 (depends on 1)

A compound of Formula (I) according to claim 1, wherein
R3 is methyl,
or a pharmaceutically acceptable salt thereof.

### Claim 3 (depends on 1)

A compound of Formula (I) according to claim 1, wherein
X is CH and
R1 is a fluorine atom,
or a pharmaceutically acceptable salt thereof.

### Claim 4 (depends on 1)

A compound of Formula (I) according to claim 1, wherein
X is N and
R1 is a hydrogen atom,
or a pharmaceutically acceptable salt thereof.

### Claim 5 (depends on 1)

A compound of Formula (I) according to claim 1, wherein
R4 is carboxy, C1-3 alkoxy-carbonyl, aminocarbonyl or N—(C1-3alkyl)-aminocarbonyl group,
wherein the methyl moiety of the above-mentioned N-(methyl)-aminocarbonyl group may optionally be substituted with a piperidinyl, N-methyl-piperidinyl or morpholinyl group, each bound via a carbon atom, and wherein the ethyl resp. propyl moiety of the above-mentioned N—(C2-3alkyl)-aminocarbonyl group may optionally be terminally substituted with hydroxy, methoxy, amino, N-methyl-amino, N,N-dimethyl-amino, morpholino, imidazolyl, 4-methyl-piperazinyl, 1-methyl-pyrrolidinyl, piperidinyl, pyrrolidinyl or 4-hydroxy-piperidino group,
or a pharmaceutically acceptable salt thereof.

### Claim 6 (depends on 5)

A compound of Formula (I) according to claim 5, wherein
R4 is aminocarbonyl or N—(C1-3alkyl)-aminocarbonyl group,
wherein the methyl moiety of the above-mentioned N-(methyl)-aminocarbonyl group may optionally be substituted with a piperidinyl, N-methyl-piperidinyl or morpholinyl group, each bound via a carbon atom, and wherein the ethyl resp. propyl moiety of the above-mentioned N—(C2-3alkyl)-aminocarbonyl group may optionally be terminally substituted with hydroxy, methoxy, amino, N-methyl-amino, N,N-dimethyl-amino, morpholino, imidazolyl, 4-methyl-piperazinyl, 1-methyl-pyrrolidinyl, piperidinyl, pyrrolidinyl or 4-hydroxy-piperidino group,
or a pharmaceutically acceptable salt thereof.

### Claim 7 (depends on 1)

A compound of Formula (I) according to claim 1, wherein
R2 is cyclopentyl substituted with one or two hydroxy or methoxy groups or with an amino, methylcarbonyl-amino, N-methyl-N-methylcarbonyl-amino group or wherein two adjacent carbon atoms are linked to each other via a —O—CH2—O— or —O—C(CH3)2—O— group, or
cyclohexyl substituted with one or two fluorine atoms or one or two hydroxy or methoxy groups or an oxo, C1-3 alkoxy-carbonyl, morpholino, methyl-piperidinyl or an amino group, wherein the hydrogen atoms of the amino group my optionally independently be replaced with a methyl, methylcarbonyl, 2-methoxy-ethyl or methylsulfonyl group, or wherein two adjacent carbon atoms are linked to each other via —O—C(CH3)2—O— group or wherein two hydrogen atoms attached to the same carbon atom are replaced by a —O—(CH2)2—O— group,
or a pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 7)

A compound of formula (I) according to claim 7, wherein
R2 is cyclohexyl substituted with one hydroxy or methoxy group,
cyclopentyl substituted with one hydroxy, methoxy, methylcarbonyl-amino or N-methyl-N-methylcarbonyl-amino group or cyclopentyl, wherein two adjacent carbon atoms are linked to each other via a —O—CH2—O— group, or
cyclobutyl substituted with a methylcarbonyl-amino or methylcarbonyl-N(methyl)-amino group,
or a pharmaceutically acceptable salt thereof.

### Claim 9 (depends on 1)

A compound of Formula (I) according to claim 1 selected from a group consisting of:
or a pharmaceutically acceptable salt thereof.

### Claim 10 (depends on 1)

A pharmaceutically acceptable salt of a compound according to claim 1.

### Claim 11 (depends on 1)

A pharmaceutical composition comprising a compound according to claim 1 or a pharmaceutically acceptable salt thereof and optionally a pharmaceutically acceptable carrier.

### Claim 12 (depends on 11)

A pharmaceutical composition according to claim 11 further comprising an additional therapeutic agent.

### Claim 13 (depends on 12)

A pharmaceutical composition according to claim 12 wherein the additional therapeutic agent is selected from an antidiabetic agent, a lipid lowering agent, a cardiovascular agent, an antihypertensive agent, a diuretic agent, a thrombocyte aggregation inhibitor, an antineoplastic agent and an anti-obesity agent.

### Claim 14 (depends on 1)

A method of treating a disease mediated by the activity of the kinase activity of Mnk1 or Mnk2 (Mnk2a, Mnk2b) or variants thereof comprising administering to a patient in need an effective amount of a compound defined in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 15 (depends on 1)

A method of preventing or treating a disease selected from metabolic diseases, hematopoietic disorders, neurodegenerative diseases, kidney damage, inflammatory disorders and cancer and their consecutive complications and diseases thereof comprising administering to a patient in need an effective amount of a compound defined in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 16 (depends on 1)

A method of preventing or treating a disease selected from metabolic diseases of the carbohydrate and/or lipid metabolism and their consecutive complications and disorders thereof comprising administering to a patient in need an effective amount of a compound of defined in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 17 (depends on 1)

A method of preventing or treating diabetes comprising administering to a patient in need an effective amount of a compound defined in claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 18 (depends on 14)

A method according to claim 14 wherein the compound is administered to a patient concomitantly or sequentially in combination with an additional therapeutic agent.

### Claim 19 (depends on 1)

A method of preventing or treating cytokine related disorders comprising administering to a patient in need an effecitve amount of a compound according to claim 1 or a pharmaceutically acceptable salt thereof.

### Claim 20 (depends on 19)

The method of claim 19 wherein the compound is administered to a patient concomitantly or sequentially in combination with an additional therapeutic agent.

### Claim 21 (depends on 20)

The method according to claim 20, wherein the additional therapeutic agent is selected from a histamine antagonist, a bradikinin antagonist, serotonin antagonist, leukotriene, an anti-asthmatic, an NSAID, an antipyretic, a corticosteroid, an antibiotic, an analgetic, a uricosuric agent, chemotherapeutic agent, an anti gout agent, a bronchodilator, a cyclooxygenase-2 inhibitor, a steroid, a 5-lipoxygenase inhibitor, an immunosuppressive agent, a leukotriene antagonist, a cytostatic agent, an antineoplastic agent, a mTor inhibitor, a Tyrosine kinase inhibitor, antibodies or fragments thereof against cytokines and soluble parts (fragments) of cytokine receptors.
